Triantafyllia Koletsa1, Georgios Petrakis1, Georgia Karayannopoulou1, Sylvie Euvrard2, Jean Kanitakis3,4. 1. Department of Pathology, AHEPA Hospital, Aristotelian University of Thessaloniki, Thessaloniki, Greece. 2. Department of Dermatology, Ed. Herriot Hospital, Lyon, France. 3. Department of Dermatology, Ed. Herriot Hospital, Lyon, France jean.kanitakis@univ-lyon1.fr. 4. Department of Pathology, Ed. Herriot Hospital, Lyon, France.
Abstract
BACKGROUND/AIM: Inhibitors of the mammalian target of rapamycin (mTORis) exert immunosuppressive and antitumor effects and are used in organ-transplant recipients (OTR) as immunosuppressants able to reduce skin tumor burden. This study investigated the effects of mTORis on the expression of mTOR pathway proteins in cutaneous squamous-cell carcinomas (SCC) developing in OTR, before and after switching to mTORis. MATERIALS AND METHODS: An immunohistochemical study was performed on 23 SCC sections excised from OTR with post-transplant SCC, before or after switch to mTORis, with antibodies against pAkt, pmTOR and PI3K. RESULTS: pmTOR expression was found in 8/12 SCC pre-switch, and in 8/11 SCC post-switch, to mTORis. All (but 2) SCC expressed PI3K, and all SCCs expressed pAkt. CONCLUSION: mTORis do not significantly change the immunohistochemical expression of molecules upstream of the mTOR inhibition (pmTOR, PI3K, pAkt), in cutaneous SCC. Copyright
BACKGROUND/AIM: Inhibitors of the mammalian target of rapamycin (mTORis) exert immunosuppressive and antitumor effects and are used in organ-transplant recipients (OTR) as immunosuppressants able to reduce skin tumor burden. This study investigated the effects of mTORis on the expression of mTOR pathway proteins in cutaneous squamous-cell carcinomas (SCC) developing in OTR, before and after switching to mTORis. MATERIALS AND METHODS: An immunohistochemical study was performed on 23 SCC sections excised from OTR with post-transplant SCC, before or after switch to mTORis, with antibodies against pAkt, pmTOR and PI3K. RESULTS: pmTOR expression was found in 8/12 SCC pre-switch, and in 8/11 SCC post-switch, to mTORis. All (but 2) SCC expressed PI3K, and all SCCs expressed pAkt. CONCLUSION: mTORis do not significantly change the immunohistochemical expression of molecules upstream of the mTOR inhibition (pmTOR, PI3K, pAkt), in cutaneous SCC. Copyright
Authors: Ida Ghlichloo; Zhongbo Jin; Ruohao Fan; Caili Tong; Petr Starostik; Jeremy R Chien; Jinping Lai Journal: In Vivo Date: 2022 Jan-Feb Impact factor: 2.155
Authors: Elliot D Blue; S Caleb Freeman; Marissa B Lobl; Dillon D Clarey; Rose L Fredrick; Ashley Wysong; Melodi Javid Whitley Journal: JID Innov Date: 2022-03-30